Published Date : Jun 14, 2016
ALBANY, NY, June 14, 2016 - MarketResearchReports.biz has added the report “Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market,” to its offering. This report provides a detailed reports of the market and comprises the major opportunities in the Asia Pacific non-small cell lung cancer therapeutics market across China, India, Australia, Japan, and South Korea.
The report also incorporates attributes such as the patent expiry’s impact on the currently present branded therapies and the progress of late-stage therapies in the clinical trials taking place within the Asia Pacific non-small cell lung cancer (NSCLC) therapeutics market. The snapshot of the market has also been presented by covering the prime technological developments taking place in the market in the forecast period 2015 to 2022. The poor prognosis of this type of cancer, particularly in patients having an advanced stage of NSCLC has led to an increased need for better therapeutic options in the Asia Pacific region. According to the report, the Asia Pacific NSCLC market stood at $2.7 bn in 2015 and is expected to reach $4.9 bn by 2022, by rising at a CAGR of 8.70% from 2015 to 2022.
The increasing population, growing pollution, and the rising count of passive smokers in Asia Pacific are the prime factors propelling the development of the NSCLC therapeutics market here. In addition, the high count of healthcare reforms and the expanding health insurance systems in Asia Pacific will also augment the growth of the market. Furthermore, the increasing mutation testing and the plethora of second-line and first-line therapy options in Asia Pacific will impact the market positively. However, the patent expiration of branded therapies and the high costs involved in therapeutics may inhibit the development of the Asia Pacific NSCLC therapeutics market.
The report starts by presenting the disease overview section. Under this section, the study highlights the symptoms as well as epidemiology of NSCLC. More than 50% of the patients suffering from NSCLC are over the age of 65, hence this type of cancer is more common in older adults. In addition, this type of cancer is very common with presently 85% of lung cancers being NSCLCs globally. The major sub-types of NSCLC are large cell carcinoma, adenocarcinoma, and squamous cell carcinoma. NSCLC is majorly treated by using surgical resection along with curative intent. Although, this kind of cancer is comparatively insensitive to chemotherapy in comparison with small cell cancer, still chemotherapy is used for its treatment, particularly before the patient is operated and post-operatively.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/725317
The major options for treatment of NSCLC have been covered in the next part of the report. This section highlights the maintenance therapy, treatment algorithm, adjuvant therapy, first-line, second-line, and third-line treatments utilized for treating this type of cancer. Both the pipeline as well as marketed products in the Asia Pacific NSCLC therapeutics market have been reviewed under this part of the study. A mAb checkpoint inhibitor employed for PD1, named Opdivo, has recently been approved and introduced in the market for treating patients having metastatic squamous NSCLC in Australia and Japan in 2016 and 2015, respectively. Currently, patients having non-squamous histology are being treated by using successful therapies such as Alimta, while patients with activating mutations in EFFR or ALK are given targeted 4 kinds of targeted therapies, namely Iressa, Tarceva, Gilotrif, and Xalkori.
AstraZeneca, OncoGenex, Bristol-Myers Squibb, and Peregrine Pharmaceuticals, among others are the prominent players in the Asia Pacific NSCLC therapeutics market.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org